earnings digest pharmaceuticals eli lilly &amp co eli lilly &amp co s second quarter profit dropped as a result of charges related to the acquisitions of hypnion and ivy animal health inc but revenue rose boosted by strong sales of antidepressant cymbalta the indianapolis drug maker also raised its full year earnings forecast zyprexa lillys top selling product had sales of &# billion up 
